Media headlines about Thermo Fisher Scientific (NYSE:TMO) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 45.8416691177493 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of analysts recently weighed in on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Leerink Swann reaffirmed an “outperform” rating and issued a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective for the company. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $212.21.

Thermo Fisher Scientific (TMO) traded up $1.10 during mid-day trading on Friday, hitting $213.51. 1,440,000 shares of the company’s stock traded hands, compared to its average volume of 1,570,000. The stock has a market capitalization of $85,170.00, a price-to-earnings ratio of 36.25, a price-to-earnings-growth ratio of 1.72 and a beta of 1.06. Thermo Fisher Scientific has a 1-year low of $140.00 and a 1-year high of $214.57. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.03 earnings per share. sell-side analysts expect that Thermo Fisher Scientific will post 9.36 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, January 15th. Shareholders of record on Friday, December 15th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.28%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Thermo Fisher Scientific (TMO) Receives News Impact Rating of 0.11” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/01/19/thermo-fisher-scientific-tmo-receives-news-impact-rating-of-0-11.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.